| 80 | 0 | 32 |
| 下载次数 | 被引频次 | 阅读次数 |
<正> 非甾体类抗雄激素药氟他胺是70年代初期开发的抗前列腺癌药。前列腺癌是老年人中常见的恶性肿瘤,传统的治疗方法包括外科手术及药物治疗。由于前列腺位置隐蔽,早期前列腺癌的临床症状和体征并不典型,且缺乏特异性灵敏的诊断方法,约50％～80％的病人待确诊时已发生了转移。因此,
Abstract：1 曾金云。前列腺癌的内分泌治疗与堆激素受体。国外医学泌尿系统分册 1989;11:11
2 Huggins. C, Hodges. CV. Studies on prostatic cancer. Cancer Research 1941; 1: 293～297
3 Rudolph. NR:A biological profile of nonsieroidal antiandrogens SCH13521． Endocrinology ??1972; 91:427
4 Edwin. A. On the mechanism of the anti-androgenic action of fiutamide in thd rats. Endocrinology 1974; 4:532～541
5 Liao SS. Action of a nonsteroidal antiandrogens flutamide on the receptor binding and nuclear retention of 5-αDTH in rats ventral prostate. Endocrinology 1974; 94: 1205
6 Kontula. KK, et al. Effect of a nonsteroidal antiandrogen, flutamide on androgen receptor dynamics and ornithine decarboxylase gene expression in mouse kidney. Endocrinoiogy 1985; 116: 226～233
7 Simard J, et al. Characteristics of interaction of the antiandrogen flutamide with the androgen receptor in various target tissues. Molecular and Cellular. Endocrinology 1986; 44: 261～270
8 Rudolph. NR, et al. Pharmacology and pharmacokinetics of Flutamide. Urology (supplement) 1989; 34: 19～21
9 Neri. RO, et al. Studies on the biology and mechanism of action of non-steroid antiandrogens. Androgens and antiandrogens 1977; 179～189
10 Symes. EK, et al. The nuclear uptake of androgen by human benign prostate in vitro: action of antiandrogen. Journal of Urology 1978; 120: 180～183
11 Eil. C, Edelson. SK, et al. The use of human skin fibroblasis to obtainpotency estimates of drug binding to androgen receptors. Journal of clinical Endocrinology and Metabolism 1984; 59: 51～53
12 Schulz. M, et al. The pharmacokinetics of flutamide and it's majoy metabolites after a single oral dose and during chronic treatment. European Journal of clinical Pharmacology 1988; 34: 633～636
13 Knuth. UA, et al. Effect of flutamide or CPA acetate on pituitary and testicular hormones in normal men. Journal of Clinical Endocrinology and Metabolism 1984; 59: 963～969
14 Millard. OH, et al. Preliminary results in thirty patients with stage D2 prostatic cancer treated by total androgen blockade. Journal of Drug Development 1987; 1: 26～33
15 Radwanski. EN, et al. Single and multiple dose pharmacokinetic evaluation of flutamide in normal geriatric volunteers. Journal of Clinical Pharmacology 1989; 29:554～558
16 Bernard. KN, et al. Disposiition of a mew, nonsteroid antiandrogen flutamide in men following a single oral 200mg dose. Journal of Clinical Endocrinology and Metabolism 1975; 41: 373～379
17 Michael. A, et al. Flutamide in the treatment of advanced prostatic cancer. Journal of Urology 1986; 135: 203A
18 Sogani. PC, et al. Experience with flutamide in patients with advanced prostatic cancer without prior endocrine therapy. Cancer 1984; 54: 744～750
19 Kassem. NY, et al. Flutamide in advanced cancer of the prostate. Clinical pharmacology and Therapeutics 1982; 31: 238
20 Sarfaty. BG, et al. Phase Ⅱ study of flutamide in advanced prostate cancer. British Journal of Urology 1986; 58: 94
21 Evenson. M, et al. Flutamide in advanced prostatic cancer. Prostate 1983; 4: 666
22 Labrie. F, et al. Combination therapy with flutamide and castration (Orchiectomy or LHRH agonist). Journal of Steroid Biochemistry 1987; 27: 525～532
23 Labric. F, et al. Combination therapy with flutamide and castration (LHRH agonist ororchiectomy) in previously untreated patients with clinical stage D2 prostate cancer: today's therapy of choice. Journal of Steroid Biochemistry 1988;30: 107～117
24 Kassem. NY, et al. Flutamide in advanced cancer of the prostate. Clinical Pharmacology and Therapeuties 1982; 31: 238
基本信息:
DOI：10.19577/j.cnki.issn10074406.1995.01.012
中图分类号:R979.1
引用信息:
[1]张宏伟,李端.非甾体类抗雄激素药氟他胺的研究概况[J].临床药学,1995(01):27-30.DOI:10.19577/j.cnki.issn10074406.1995.01.012.
1995-03-30
1995-03-30